FDA approves Medtronic's Affera all-in-one pulsed field ablation system
Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again. | Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation for afib,
Medtronic’s Affera PFA snags FDA approval
Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter. Affera brings the first radiofrequency/PFA device to the cardiac ablation market and ups the ante in the PFA competition.
FDA approves Medtronic’s Affera mapping and ablation system with Sphere-9 catheter
This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.
A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter,
Medtronic wins FDA approval for Affera mapping and ablation system
Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.
Medtronic’s Affera ablation system granted FDA approval
Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping
FDA approves Medtronic’s Affera cardiac mapping and ablation system and Sphere-9 catheter
Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA and RF energy.
Medtronic Gets FDA Approval for Affera Technology
Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter. The healthcare company said it is now the first and only company with two pulsed field ablation technologies available for patients with the heart-disease persistent atrial fibrillation following the Dec.
Medtronic’s Innovative Affera System Gains FDA Approval, Boosting EP Market Prospects
Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price
FierceBiotech2d
Boston Scientific posts 177% EP growth, pauses Farapulse study in first-line afib
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...
Hosted on MSN2d
Boston Scientific's Rockstar Segment Just Fumbled — And So Did Its Shares
Boston Scientific stock pulled back from its run at a record high on Wednesday despite reporting a sweeping third-quarter beat.
medtechdive2d
Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...
Boston Scientific Unveils Cardiac Mapping For FARAPULSE Pulsed Field Ablation System
Boston Scientific Corp. (BSX) said it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV ...